In vitro diagnostic tests are the tests are used for in vitro examination of specimens derived from the human body to provide information for screening, diagnosis, or treatment monitoring purposes. The rising prevalence of chronic disease in Italy has been the primary driver for the growth of this market. This rising prevalence has increased the demand for early and effective diagnostic tests. The use of point-of-care (POC) diagnostics has also increased over the past few decades. Moreover, increasing awareness and acceptance of personalized medicine and companion diagnostics have also helped he market growth.
Key Market Trends
Application in Diabetes is expected to Cover a Large Share of the Market
Diabetes is a chronic disorder resulting from insulin deficiency and hyperglycemia and has a high risk of development of complications for the eyes, kidneys, peripheral nerves, heart, and blood vessels. Quick diagnosis and early prevention are critical for the control of the disease status. Traditional biosensors such as glucose meters and glycohemoglobin test kits are widely used in vitro for this purpose because they are the two major indicators directly involved in diabetes diagnosis and long-term management. The market size and huge demand for these tests make it a model disease to develop new approaches to biosensors.
The prevalence of diabetes has increased in Italy over the past few decades. As per a 2017 report by the Italian National Institute of Statistics (ISTAT), in 2016 more than 3.2 million people in Italy has been reported to suffer from diabetes, which accounted for 5.3% of the total population. Moreover, 16.5% among people aged 65 and over suffered from diabetes. These increasing incidence of diabetes is thus expected to increase the demand for early diagnostics tests, which will help the growth of this market.
Competitive Landscape
Italy is a developed region with well-structured healthcare system. As a result, many global players in the in-vitro diagnostics market are present in the country. Moreover, some domestic players have also been competing in the Italian market. These factors have made the region very competitive.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
Key Market Trends
Application in Diabetes is expected to Cover a Large Share of the Market
Diabetes is a chronic disorder resulting from insulin deficiency and hyperglycemia and has a high risk of development of complications for the eyes, kidneys, peripheral nerves, heart, and blood vessels. Quick diagnosis and early prevention are critical for the control of the disease status. Traditional biosensors such as glucose meters and glycohemoglobin test kits are widely used in vitro for this purpose because they are the two major indicators directly involved in diabetes diagnosis and long-term management. The market size and huge demand for these tests make it a model disease to develop new approaches to biosensors.
The prevalence of diabetes has increased in Italy over the past few decades. As per a 2017 report by the Italian National Institute of Statistics (ISTAT), in 2016 more than 3.2 million people in Italy has been reported to suffer from diabetes, which accounted for 5.3% of the total population. Moreover, 16.5% among people aged 65 and over suffered from diabetes. These increasing incidence of diabetes is thus expected to increase the demand for early diagnostics tests, which will help the growth of this market.
Competitive Landscape
Italy is a developed region with well-structured healthcare system. As a result, many global players in the in-vitro diagnostics market are present in the country. Moreover, some domestic players have also been competing in the Italian market. These factors have made the region very competitive.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format.
- 3 months of analyst support.
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Becton, Dickinson and Company
- BioMerieux
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- QIAGEN N.V.
- Siemens Healthcare GmbH
- Sysmex Corporation
- Thermo Fischer Scientific Inc.
Methodology
LOADING...
